Merck SharpDohme LLC
Corticosteroid(Merck Sharp & Dohme LLC)은 Carcinoma, Non-Small-Cell Lung 표적 ADC로, Carcinoma, Non-Small-Cell Lung 영역에서 개발·상용화 중입니다. 작용기전: binds to an inactive glucocorticoid receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 5.6% (ClinicalTrials.gov NCT02472366). 차별점: novel treatments have been invented and analyzed, it is unclear that any of them will take the position of ICSs as the first,.
Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung
Recruiting
novel treatments have been invented and analyzed, it is unclear that any of them will take the position of ICSs as the first,
binds to an inactive glucocorticoid receptor
immune-mediated condition of the gastrointestinal tract with highly variable treatment responses
apoptosis, pyroptosis, and ferroptosis), and activation of pro-fibrotic cascades most notably TGF-β1/Smad2/3, NF-κB,
biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu
resistance to the effects of Dex was observed, as evidenced by the absence of changes in the glycemic curve peak, AUC, or rate of dec
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Merck SharpDohme LLC
Corticosteroid(Merck Sharp & Dohme LLC)은 Carcinoma, Non-Small-Cell Lung 표적 ADC로, Carcinoma, Non-Small-Cell Lung 영역에서 개발·상용화 중입니다. 작용기전: binds to an inactive glucocorticoid receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 5.6% (ClinicalTrials.gov NCT02472366). 차별점: novel treatments have been invented and analyzed, it is unclear that any of them will take the position of ICSs as the first,.
Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung
Recruiting
novel treatments have been invented and analyzed, it is unclear that any of them will take the position of ICSs as the first,
binds to an inactive glucocorticoid receptor
immune-mediated condition of the gastrointestinal tract with highly variable treatment responses
apoptosis, pyroptosis, and ferroptosis), and activation of pro-fibrotic cascades most notably TGF-β1/Smad2/3, NF-κB,
biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu
resistance to the effects of Dex was observed, as evidenced by the absence of changes in the glycemic curve peak, AUC, or rate of dec
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.